Business
NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset
TORONTO, March 25, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company”...
About this update from Netramark Holdings Inc
[{"type":"text","content":"NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial DatasetThe collaboration aims to uncover clinically actionable patient subpopulations and biomarker-driven treatment insights from a landmark precision-oncology trial\nTORONTO, March 25, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced a strategic research collaboration with Fondazione per la Medicina Personalizzata (FMP) to analyze its landmark ROME Phase II oncology trial dataset (NCT04591431) using NetraMark’s proprietary NetraAI platform, with the objective of identifying clinically actionable insights that may inform future precision-oncology strategies and clinical trial design. “NetraAI was built to reveal clinically meaningful structure within complex trial datasets by identifying compact, interpretable patient subpopulations where treatment effects become detectable,” said Dr. Joseph Geraci, Founder, Chief Scientific and Technology Officer of NetraMark. “We are pleased to collaborate with FMP on the ROME program and apply this methodology to potentially produce insights that can be communicated clearly to clinical stakeholders and those responsible for translating findings into trial design, regulatory strategy, and patient care.” The ROME Trial The ROME trial, reported in Nature Medicine, is a multicentre, randomized, open-label phase 2 study comparing tailored treatment to standard of care. The study evaluated patients with advanced solid tumors progressing after one or two prior lines of therapy, guided by comprehensive genomic profiling on tissue and blood and evaluated through a molecular tumor board process. In the intention-to-treat population (n=400 randomized), the trial reported improvements in overall response rate and progression-free survival for tailored treatment versus standard of care, while overall survival was similar in the context of a high crossover rate. Safety outcomes were broadly comparable between arms. Strategic and Clinical Value of the Collaboration Through th...